<DOC>
	<DOCNO>NCT01226277</DOCNO>
	<brief_summary>This open-label , multicenter , Phase I dose-escalation study design assess safety , tolerability , pharmacokinetics ( PK ) GDC-0917 patient refractory solid tumor lymphoma .</brief_summary>
	<brief_title>A Study Evaluating Safety , Tolerability Pharmacokinetics GDC-0917 Administered Patients With Refractory Solid Tumors Lymphoma</brief_title>
	<detailed_description />
	<criteria>Histologically cytologically document , locally advanced metastatic solid tumor lymphoma standard therapy either exist proven ineffective intolerable Life expectancy &gt; /= 12 week Adequate hematologic end organ function For female patient childbearing potential male patient partner childbearing potential , agreement ( patient and/or partner ) use effective form contraception continue use duration study . Clinically significant history chronic liver disease , active hepatic infection , evidence hepatic cirrhosis Grade &gt; /= 2 liver dysfunction due hepatic metastasis cancer , current alcohol abuse , active infection hepatitis B virus , hepatitis C virus Grade &gt; /= 2 fever associate constitutional symptom , clinically significant systemic infection within last month Autoimmune disease History clinically significant pulmonary disease Need chronic continuous systemic topical corticosteroid immunosuppressive therapy within 2 week prior study entry anticipate need continuous systemic corticosteroid immunosuppressive therapy study participation . Allergy hypersensitivity component GDC0917 formulation Palliative radiotherapy within 2 week prior first dose study drug treatment Cycle 1 Experimental therapy within 4 week prior first dose study drug treatment Cycle 1 Major surgical procedure significant traumatic injury within 4 week prior first dose study drug treatment Cycle 1 , anticipation need major surgery course study treatment Prior anticancer therapy within 4 week first dose study drug treatment Cycle 1 All acute drugrelated toxicity must resolve prior study entry , except alopecia Grade 1 neuropathy Current severe , uncontrolled systemic disease exclude cancer History clinically significant cardiac dysfunction History malabsorption condition would interfere enteral absorption Any history active GI bleeding within past 6 month prior screen Known HIV infection Uncontrolled ascites , due disease cancer , require weekly largevolume paracentesis 3 consecutive week prior enrollment Pregnancy , lactation , breastfeed unwillingness use birth control study 3 month last dose GDC0917 Known brain metastasis untreated , symptomatic , require therapy control symptom</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>